Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt‐Survivin‐P‐Glycoprotein Pathway
Journal of Biochemical and Molecular Toxicology · 2026-05 · 40 (5)
DOI: 10.1002/jbt.70885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 03.05.2026. Verfasst von Yasmin M Attia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Department, Pharmacology Unit, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Imatinib Mesylate, Cytidine, Survivin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) remains one of the leading causes of cancer mortality, with a poor survival rate of less than 15%. Imatinib (IM) and Zebularine (ZEB) alone have shown potential effects in CRC treatment, but their combination has not been thoroughly studied. This study investigates the potential effects of IM and ZEB in colon cancer cells to provide a novel therapeutic agent for managing CRC. Cell growth inhibition, oxidative stress markers, and cell cycle progression were assessed in HCT‐116 cells treated with IM, ZEB, and their combinations. ZEB uptake levels were analyzed by LC‐MS/MS, apoptosis was quantified by flow cytometry, and gene expression changes were analyzed by qPCR. The expression of metastatic markers, apoptotic regulators, and EGFR was assessed. Both IM and ZEB inhibited cell growth in a concentration‐dependent manner, and their combination showed synergistic effects. The combination significantly enhanced oxidative stress. The combination therapy increased apoptosis and necrosis. Furthermore, the combination induced significant S‐phase arrest in the cell cycle. The combination treatment reduced metastatic markers (MMP9, MMP2), and the apoptotic marker Caspase‐9 was upregulated. Additionally, the Bcl‐2 protein, a key regulator of apoptosis, was significantly downexpressed. Remarkably, the combination treatment showed significant inhibition in EGFR levels. Both IM and ZEB combination showed promise in the management of CRC by inducing oxidative stress, promoting apoptosis, and modulating critical genes involved in metastasis and apoptosis. Further investigation will be needed to verify their application in preclinical and clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Department, Pharmacology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
- Cancer Biology Department, Medical Biochemistry and Molecular Biology Unit. National Cancer Institute, Cairo University, Cairo, Egypt.
- Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Yasmin M Attia, Samia A Shouman, Mervat M Omran
Zitieren
APA
Attia, Y. M., Elkhoely, A., Abdelwahed, F. M., Shouman, S. A., & Omran, M. M. (2026). Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt‐Survivin‐P‐Glycoprotein Pathway. Journal of Biochemical and Molecular Toxicology, 40(5). https://doi.org/10.1002/jbt.70885
Vancouver
Attia YM, Elkhoely A, Abdelwahed FM, Shouman SA, Omran MM. Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt‐Survivin‐P‐Glycoprotein Pathway. Journal of Biochemical and Molecular Toxicology. 2026;40(5). doi:10.1002/jbt.70885
BibTeX
@article{Attia2026,
author = {Attia, Yasmin M and Elkhoely, Abeer and Abdelwahed, Fatma M and Shouman, Samia A and Omran, Mervat M},
title = {Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt‐Survivin‐P‐Glycoprotein Pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {5},
doi = {10.1002/jbt.70885}
}
EUVIMED